This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Celis, E. Search for Related Content PubMed PubMed Citation Articles by Celis, E. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Biologics Cancer Immunology: Immunotherapy

Toll-like Receptor Ligands Energize Peptide Vaccines through Multiple Paths

Immunology Program and Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida

Requests for reprints: Esteban Celis, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Phone: 813-745-1925; E-mail: ecelis{at}moffitt.org.

The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells. [Cancer Res 2007;67(17):7945–7]

This article has been cited by other articles:

				G. C. Prendergast Breaking Immune Suppression in Cancer: The Emerging Revolution in Immunotherapy Cancer Reviews Online Content, October 1, 2007; 2007(7): 13 - 14. [Full Text] [PDF]